Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
NE
NeoGenomics, Inc.
NEO
Mkt Cap
$2.14B
Volume
1.24M
Next Earnings
October 27th
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
NE
NEO
NE
NeoGenomics, Inc.
NEO
News
·
Should You Invest in the State Street SPDR S&P Health Care Services ETF (XHS)?
Mkt Cap
$2.14B
Volume
1.24M
Next Earnings
October 27th
Chart
Financials
Earnings
News
About
Insider
Filings
Should You Invest in the State Street SPDR S&P Health Care Services ETF (XHS)?
The State Street SPDR S&P Health Care Services ETF (XHS) is a passively managed healthcare services sector ETF with low costs (0.35% expense ratio) and solid year-to-date performance of 27.29%. The fund holds about 62 healthcare companies with a medium risk profile (beta of 0.93) and carries a Zacks ETF Rank of 3 (Hold), making it a reasonable option for investors seeking diversified healthcare sector exposure.
Zacks Investment Research · Sep 14, 2026
State of the Life Sciences Industry to Be Reviewed in BCC Research's 2026 Second Quarter Outlook, Spotlighting AI-Driven Discovery, Precision Oncology, and Connected Health Adoption
BCC Research's mid-year assessment highlights AI-driven discovery, precision oncology, and connected health as major growth themes in the life sciences sector. Key opportunities include smart inhalers with AI integration, genomic profiling platforms, cardiovascular drug innovations, and in vitro toxicity testing. The sector benefits from aging populations, regulatory support for non-animal testing, and emerging market expansion, though risks include patent expirations and reimbursement variability.
GlobeNewswire Inc. · Aug 25, 2026
3 Hot Trades for Insiders, But Are They Good Buys for Investors?
Insider activity increased in stocks such as Hudson Pacific Properties, NeoGenomics, and Carvana, signaling opportunities for traders and investors. The article examines who is buying, the forces driving their underlying markets, and the potential upside.
Investing.com · Jun 25, 2025
It's Not Too Late to Jump on These Under-the-Radar Momentum Plays
Three stocks across multiple sectors may draw the attention of investors looking for a momentum play - Oddity Tech Ltd, NeoGenomics Inc, and Comfort Systems USA Inc. These companies have seen significant share price improvements and positive analyst ratings, suggesting potential for continued upside.
Investing.com · May 6, 2025
Minimal Residual Disease Testing Market Forecast Report, 2025-2030 - Precision Medicine and Early Relapse Detection Drive MRD Testing Demand Worldwide
The Minimal Residual Disease (MRD) Testing Market is expected to grow at a CAGR of 11.18% from 2025 to 2030, driven by advancements in diagnostic technologies and the increasing focus on precision medicine and early relapse detection.
GlobeNewswire Inc. · Apr 8, 2025
Not Just a DEX: How Pineapple’s Mystery Marketing is Changing the Game
Pineapple is a next-generation decentralized exchange that combines AI-driven community interaction, cutting-edge trading tools, and a unique narrative-driven marketing approach to revolutionize DeFi trading and engagement.
GlobeNewswire Inc. · Feb 17, 2025
Cutting-Edge Cancer Therapies Lead the Way into a Transformative Year
The article discusses the promising developments in cancer research, including new therapies and innovative technologies, and highlights recent updates from several biotech companies working on cutting-edge cancer treatments.
Benzinga · Jan 15, 2025
Gene Panel Market to Surpass USD 11.75 Billion by 2031 | SkyQuest Technology
The global gene panel market is projected to reach $11.75 billion by 2031, growing at a CAGR of 19.30% during the forecast period. The market growth is driven by advancements in genomic research, rising prevalence of genetic disorders, and growing awareness of genetic testing.
GlobeNewswire Inc. · Nov 22, 2024
Laboratory-Developed Tests (LDTs) World Market Forecast Report to 2028, with Coverage of the Effects of the FDA's New "Medical Devices: Laboratory Developed Tests" Rule, Passed in April 2024
This report analyzes the global market for laboratory-developed tests (LDTs), including the impact of new FDA regulations introduced in 2024. It covers the LDT services market and the market for LDT products sold to clinical laboratories, with a focus on key segments like infectious disease and oncology.
GlobeNewswire Inc. · Aug 15, 2024
Where NeoGenomics Stands With Analysts
Ratings for NeoGenomics (NASDAQ:NEO) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 3 1 0 0 0 Last 30D 1 0 0 0 0 1M Ago 0 0 0 0 0 2M Ago 0 0 0 0 0 3M Ago 2 1 0 0 0 Insights from analysts' 12-month price targets are revealed, presenting an average target of $20.5, a high estimate of $24.00, and a low estimate of $19.00. This current average reflects an increase of 2.5% from the previous average price target of $20.00. Breaking Down Analyst Ratings: A Detailed Examination In examining recent analyst actions, we gain insights into how financial experts perceive NeoGenomics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Mike Matson Needham Lowers Buy $19.00 $24.00 David Westenberg Piper Sandler Raises Overweight $20.00 $18.00 Matthew Sykes Goldman Sachs Raises Buy $19.00 $17.00 Mike Matson Needham Raises Buy $24.00 $21.00 Key Insights: Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to NeoGenomics. This offers insight into analysts' perspectives on the current state of the company. Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from ...Full story available on Benzinga.com
Benzinga · Apr 30, 2024
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
NE
NEO
NeoGenomics, Inc.
Buy
Sell
Market
Limit
Soon
NEO
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any NEO yet.
Related Tickers
Earnings